According to a recent Reuters article, the FDA has asked three major drug companies to update safety restrictions for their arthritis drugs. The drugs in question belong to the class of treatments known as JAK inhibitors, which treat rheumatoid arthritis. All three drugs: Pfizer’s Xeljanz, AbbVie’s Rinvoq, and Eli Lilly’s Olumiant, currently have boxed warnings about blood clots and lymphoma. With updated warnings, the FDA is essentially pushing back the drugs’ place in the treatment sequence and limiting their use.
New Bionic Arm Restores Natural Movement for Amputees
Touch and hand movement combined with intuitive motor control allow amputees to behave normally.
Sep 6, 2021
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
